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Abstract
Background: Polyamine metabolism has a critical role in cell death and proliferation representing a potential
target for intervention in breast cancer (BC). This study investigates the expression of spermine oxidase (SMO) and
its prognostic significance in BC. Biochemical analysis of Spm analogues BENSpm and CPENSpm, utilized in
anticancer therapy, was also carried out to test their property in silico and in vitro on the recombinant SMO
enzyme.
Methods: BC tissue samples were analyzed for SMO transcript level and SMO activity. Student’s t test was applied
to evaluate the significance of the differences in value observed in T and NT samples. The structure modeling
analysis of BENSpm and CPENSpm complexes formed with the SMO enzyme and their inhibitory activity, assayed
by in vitro experiments, were examined.
Results: Both the expression level of SMO mRNA and SMO enzyme activity were significantly lower in BC samples
compared to NT samples. The modeling of BENSpm and CPENSpm complexes formed with SMO and their
inhibition properties showed that both were good inhibitors.
Conclusions: This study shows that underexpression of SMO is a negative marker in BC. The SMO induction is a
remarkable chemotherapeutical target. The BENSpm and CPENSpm are efficient SMO inhibitors. The inhibition
properties shown by these analogues could explain their poor positive outcomes in Phases I and II of clinical trials.
Background
Breast cancer (BC) is a common disease that generally
occurs in women over the age of 50, and the risk is
especially high for women over age 60. Patients who
undergo curative surgery may develop metastasis during
follow-up, and the side effects of cancer treatment
depend mainly on the type and extent of the treatment.
One of the major therapeutic problems is that tumors
initially responsive to chemotherapeutic approaches can
progress to more aggressive forms poorly responsive to
therapies. The need for antineoplastic compounds with
novel mechanisms of action is therefore of high social
impact. The polyamines (PA) are polycations essential
for cell growth and differentiation [1]. In BC cells, pro-
liferative signals transduced by estradiol and growth fac-
tors are modulated by PA, by the induction of ornithine
decarboxylase (ODC) [2,3]. Increased PA levels are often
associated with malignant transformation and mainte-
nance of the neoplastic phenotype [4]. Cells finely regu-
late PA concentrations by de novo synthesis from amino
acid precursors and PA uptake from diet, with the bal-
ancing inter-conversion, stepwise degradation and efflux.
In the last decade PA metabolism has been studied in
detail and the enzymes involved in the PA biosynthesis
and catabolism well characterized [5,6]. PA facilitate the
interactions of transcription factors, such as estrogen
receptors and nuclear factor kB, with their specific
response element [7] and are also involved in the prolif-
eration of ER-negative and highly invasive models of
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tumor cells [8]. Consequently, PA pathway is an impor-
tant target for drug development for BC [9]. A recent
strategy in anticancer therapy is to exploit the self-
regulatory nature of PA metabolism through the use of
PA analogues to affect PA homeostasis [10]. The impor-
tance of the PA catabolic pathway has been re-evaluated
[5,6], since its involvement in determining the cell
response to antitumor PA analogues has been demon-
strated [11]. An analysis of spermidine/spermine
N1-acetyltransferase (SSAT) and N1-acetylpolyamine
oxidase (APAO) enzyme activities in human BC tissue
has been carried out by Wallace et al. [12]. This analysis
correlates the higher level of acetylated polyamines
(acetylPA) in malignant tumors, with the decreasing
activity of APAO, concurrent with the increase of SSAT
activity [12].
To determine the incidence of spermine (Spm) analo-
gues in BC treatments, we previously evaluated the level
of spermine oxidase (SMO) expression in BC tissues.
Our results point out that SMO enzyme activity, charac-
terized by a Spm substrate specificity, is significantly
lower in BC than in healthy tissues.
Among the Spm analogues, bis(ethyl)norspermine
(BENSpm) has been well characterized and underwent
Phase I and II clinical trials [13,14]. The antiproliferative
effects of BENSpm on some human BC cell lines, like
MDA-MB-231 cells, seem to be mediated in part
through the production of H2O2 by SMO and by the
export of acetylPA formed by the induction of SSAT
activity [11]. Results from Phase II study of therapeutic
use of BENSpm against advanced refractory BC revealed
that BENSpm was not active as a single agent [14].
Extension of this study has been recently carried out to
demonstrate the ability of BENSpm to synergize with
other standard chemotherapeutic agents on the treat-
ment of some human BC cell lines [15]. The second
generation Spm analogue N1-ethyl-N11-(cyclopropyl)-
methyl-4,8-diazaundecane (CPENSpm) [16] has demon-
strated lower toxicity and greater therapeutic efficacy
than the first generation compounds. CPENSpm has
been used in combination with other cytotoxic drugs in
the treatment of BC cell lines, but it demonstrates to be
cell type specific [17,18]. Although experimental proto-
cols were promising on the clinical use [19], BENSpm
Phase I and II clinical trials gave poor positive outcomes
[14,18,20,21]. Analogously, the utilization of the
CPENSpm has produced results similar to those
obtained with the BENSpm treatments [22].
In this framework, we perform a first experimental
study to correlate the level of SMO expression in BC
tissues and structure modeling analysis of the complexes
of BENSpm and CPENSpm formed with the SMO
enzyme. Since the cellular mechanism of BENSpm and
CPENSpm action is still unclear, we analyze if these
Spm analogues are inhibitors of the SMO enzyme [5,6].
Structure modeling analysis of the complexes of
BENSpm and CPENSpm formed with the SMO enzyme
supported the hypothesis that these analogues could
bind in the catalytic site of the SMO protein. The Ki
values of BENSpm and CPENSpm have also been mea-
sured, revealing that both analogues behave like SMO
inhibitors. The inhibitory role of Spm analogues and the
low level of SMO in BC tissues taken together, could
explain the poor positive outcome of both BENSpm, in
Phases I and II of clinical trials, and CPENSpm, due to
a lower H2O2 production inside tumor mass [11].
Methods
Patients
Patients were admitted to the Department of Breast Sur-
gery at San Camillo-Forlanini Hospital (Rome, Italy),
investigations were carried out in all patients before sur-
gery: mammography and breast ultrasound, breast MRI if
requested, breast microbiopsy with Mammotome or Tru-
cut tecniques, blood tests (hemoglobin and full blood
count, urea and electrolytes, liver function tests), chest
radiography. Twenty patients were selected based on pri-
mary breast carcinoma that have not been previously trea-
ted with chemotherapy or radiotherapy. The size of the
breast tumor was measured clinically using the standard
tumor size grading system (TNM). Immediately after
removal of the tumor from the patients, a tumor (T) sam-
ple measuring ~0.5 cm in diameter was removed from the
tumor mass, cooled immediately with dry ice, and then
stored at -80°C until analyses were undertaken. As a con-
trol, a piece of nontumor (NT) breast tissue (1 cm of dia-
meter) was removed as far away as possible from the
quadrant of breast containing tumor. NT samples were
treated with the same protocol as the T samples.
Before surgical procedure all patients signed an
informed medical consent form, previously approved by
the Institutional Ethical Committee and the Medical
Board of the San Camillo-Forlanini Hospital.
Histology
The histological type and grade for breast tumors were
determined by an author (RG) of the present work, who
is an expert breast pathologist.
PCR analysis
The relative levels of human SMO, APAO, ODC, SSAT,
b-actin and glyceraldehyde-3-phosphate dehydrogenase
(GADPH) transcripts were measured by semiquantitative
RT-PCR with specific primers (Additional file 1: Table S1)
as described in Cervelli et al. [23]. Data obtained from sin-
gle patients were pooled and analyzed to produce an aver-
age level of expression. The RT-PCRs were normalized by
comparison either with the b-actin or the GADPH
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controls according to the number of PCR cycles reaction
adopted. Further control reaction mixtures, either without
template (not shown) or RT enzyme (not shown), were
uniformly negative. Results were quantified by densitome-
try, using the BioRad Multianalyst software (BioRad,
Hercules, CA). An estimate of the relative RT-PCR ampli-
fied product amounts was obtained by dividing the area of
gel bands by the area of the relative control, alternatively
b-actin or GADPH gel band. Data points are the means
(Standard Deviation, SD) of three to five separate experi-
ments, each performed in duplicate. The p values were
measured with the Student’s t test.
Analysis of enzymatic activities
SMO and APAO activities on BC tissue homogenates
were determined according to Wang et al. [24]. Two hun-
dred and fifty μg of tissue sample was used for the assay
utilizing Spm and N1-acetylated Spm as substrates for
SMO and APAO, respectively. In particular, SMO and
APAO enzymatic activities were determined by measuring
the production of H2O2 as pmol produced/mg protein/h,
following the oxidation of their specific substrates. Protein
content was estimated by the method of Bradford [25]. In
details, enzyme activity was assayed in 83 mM glycine buf-
fer, pH 8.0, 5.0 nmol luminol, 20 μg horseradish peroxi-
dase, 0.2 mM 2-bromoethylamine (copper-containing
amine oxidase inhibitor/catalase inhibitor), 15 μM depre-
nyl (mitochondrial oxidase B inhibitor), 0.15 mM clorgy-
line (mitochondrial oxidase A inhibitor) and 250 μM Spm
or alternatively N1-acetylated Spm as the substrate. All
reagents with the exception of substrate were combined in
a volume of 250 μl and incubated for 2 minutes at 37°C,
transferred to the luminometer where substrate was
added, and the resulting chemiluminescence was inte-
grated over 40 seconds. Both ODC and SSAT activities
were determined as pmol CO2 produced/mg protein/h by
using 14C-labeled substrate and scintillation counting of
end metabolized products. BC tissues were sonicated and
centrifuged at 22,000 g for 10 min at 4°C.
The SSAT enzyme activity was determined as
described by Chen et al. [26]. In particular, 75 μg of
homogenate BC tissue sample in a final volume of 50 μl
included 10 μl of 5.5 M Bicine buffer (pH 8.0), 5 μl of
30 mM Spd, 10 μl of doubly distilled water, 5 μl of
0.1 mM [14C]acetyl-CoA (53 mCi/mmol; Sigma) and 20
μl of each sample. The mixture was incubated for 5 min
at 37°C. The enzyme reaction was stopped by the addi-
tion of 20 μl 0.5 M hydroxylamine hydrochloride, and
the mixture was heated in boiling water for 3 min. The
resulting samples were centrifuged (22,000 g), and an
aliquot of 50 μl was spotted onto Whatman P81 phos-
phocellulose discs and counted for radioactivity in a
liquid-scintillation counter.
The ODC enzyme activity was determined as follows:
100 μg of homogenate BC tissue sample in a final
volume of 100 μl including 20 mM Tris Buffer (pH 7.5),
1 mM EDTA, 0.1 mM Piridoxal 5’ POH, 5 mM DTT,
0.1 mM [14C] L-Ornithine-carboxy (55 mCi/nmol;
Sigma) and 0.4 mM L-Ornithine was put in a screwed-
cap plastic “bijoux” vial. A disk of filter paper, embedded
with 30 μl of 2N NaOH, was screwed with the cap on
the top of the vial. The mixture was incubated for
30 min at 37°C. The enzyme reaction was stopped by
the addition of 200 μl of 10% TCA, then the mixture
was further incubated for 10 min at 37°C to ensure
complete CO2 adsorption on the filter paper that was
finally counted for radioactivity in a liquid-scintillation
counter. Statistical differences were analyzed by Wil-
coxon matched pairs signed rank test.
Molecular modeling of mSMO-BENSpm and mSMO-
CPENSpm complexes
The molecular models of the complexes formed by
MDL 72527 (N1, N4-bis(2,3-butadienyl)-1,4butanedia-
mine), BENSpm and CPENSpm with mSMO were built
using the crystal structure of maize PAO (MPAO) as a
template (PDB code: 1B37; [27]). The multiple sequence
alignment between mSMO, MPAO and other PAOs was
obtained using the program CLUSTALW [28]. Based on
this alignment, the three-dimensional structure of
mSMO was then built using Modeller [29]. mSMO-Spm
complex was then built using the FMS1-Spm complex
as a template (PDB code: 1XPQ; [30]) and this complex
was used to dock the inhibitors into mSMO active site
by superimposition of MDL 72527, BENSpm and
CPENSpm onto the Spm moiety.
Inhibition assays
The SMO activity was assayed at pH 8.5 (1.0 × 10-1 M
sodium borate buffer) and at 25°C (SMO enzyme con-
centration ranging from 2.0 × 10-8 M to 5.0 × 10-8 M).
The substrate Spm was used with a concentration ran-
ging from 4 × 10-6 M to 10 × 10-6 M in the presence or
absence of BENSpm and CPENSpm. In the enzyme
assay the BENSpm ranged between 1.8 × 10-4 M and 7.1
× 10-4 M, while CPENSpm between 9.5 × 10-5 M and
3.7 × 10-4 M. The Ki values were determined according
to the Dixon [31] graphical method. Data reported are
the average of three different experiments, each with
two replicates, standard deviation (SD) was 5%.
Results
Patient demographics
A total of 20 patients with a mean age of 72.9 ± 11.8
(SD) years were included in the study. Table 1 details
the clinic pathologic variables for each patient.
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Gene expression and enzymatic activities of SMO, APAO,
ODC and SSAT in BC and nonneoplastic breast tissues
Semi-quantitative RT-PCR indicated that the mean
expression levels of SMO mRNA are significantly lower
(p < 0.01) in T tissue than in NT tissue (Figure 1). Ana-
logously, APAO transcript was confirmed to be lower in
tumor samples than in the normal tissue (p < 0.01). On
the contrary, ODC and SSAT transcripts show an oppo-
site expression profile (p < 0.01) (Figure 1). The enzy-
matic activities measured from the same samples
paralleled the mRNA level profiles between T and NT
tissues (Figure 2). SMO, APAO, ODC and SSAT enzy-
matic activities measured on each individual sample are
reported (Additional file 2: Table S2). The SMO activity
was significantly lower (< p 0.05) in tumor tissue com-
pared with the equivalent normal tissue (Figure 2).
APAO enzymatic activity was confirmed to be signifi-
cantly lower (< p 0.05) in T samples than in the NT tis-
sues, by contrast, both ODC and SSAT activities were
significantly higher (< p 0.05) in malignant samples than
in normal tissue (Table 2).
Active site modeling of human SMO-BENSpm and SMO-
CPENSpm complexes
In order to analyze the potential inhibition properties of
BENSpm and CPENSpm (Figure 3), a comparative
structural analysis of the modeled complexes formed by
mSMO with Spm, BENSpm, CPENSpm and the PAOs
inhibitor MDL 72527 has been performed. Figure 3
shows the predicted interactions occurring between
inhibitor/analogues chemical groups and mSMO active
site residues. All three molecules analyzed are able to
establish Spm-like interactions with residues His82,
Gln200 and Tyr482. However, CPENSpm displays
potential additional interactions since its cyclopropyl
group fits well in a hydrophobic pocket formed by resi-
dues Tyr201, Tyr484 and Tyr526. This is expected to
increase the affinity of the enzyme for CPENSpm as
compared to both shorter MDL 72527 and BENSpm
compounds that do not display the bulky hydrophobic
cyclopropyl substituent.
Inhibition of mSMO by Spm analogues BENSpm and
CPENSpm
Murine recombinant SMO (mSMO) has been previously
characterized [32]. This protein shares 95% amino acid
sequence identity with the human counterpart and
shows a 100% conservation of the residues involved in
the catalytic properties [32]. The Spm analogues tested
(Figure 4) as in vitro modulators of mSMO activity
belong to two bis(alkyl)spermine classes: symmetrically
substituted (BENSpm) and asymmetrically substituted
(CPENSpm). Both molecules impair mSMO activity
competitively. The inhibition of mSMO activity by
BENSpm, CPENSpm and MDL72527 is shown in
Table 3. Values of Ki for mSMO competitive inhibition
Table 1 Patient demographics
Patient No. Age year TNM Tumoral markers Tumor grade Histological type of cancer
1 67 T4 N1A M0 E90%, P90%, K10%, C1+ II IDC
2 86 T1C N1 M0 E90%, P90%, K15%, C2+ II IDC
3 80 T1B N0 M0 E90%, P90%, K15%, CNEG II IDC
4 71 T1C N0 M0 ENEG, PNEG, K40%, C3+ III IDC
5 75 T2 N1 M0 ENEG, PNEG, K30%, CNEG III IDC
6 62 T1C N0 M0 E90%, P90%, K30%, C2+ II IDC
7 84 T4 N1 M0 E90%, PNEG, K40%, C3+ III IDC
8 76 T2 N0 M0 E90%, P90%, K30%, CNEG III IDC
9 88 T2 N0 M0 E90%, P90%, K15%, C1+ II IDC
10 50 T2 N2A M0 E90%, P90%, K20%, C2+ III IDC
11 85 T1C N1 M0 ENEG, PNEG, K40%, CNEG III IDC
12 82 T4 N1 M0 E90%, P40%, K20%, C3+ II IDC
13 53 T2 N2 M0 E90%, P90%, K30%, CNEG III ILC
14 68 T2 N1 M0 E90%, P90%, K20%, C1+ II IDC
15 66 T2 N0 M0 E90%, P90%, K30%, C2+ III IDC
16 73 T2 N1 M0 E80%, P70%, K20%, C3+ II IDC
17 64 T2 N0 M0 E80%, P70%, K30%, C2+ III IDC
18 63 TIS ENEG, PNEG, K40%, C3+ III ISDC
19 47 T2 N0 M0 E90%, P90%, K30%, CNEG III IDC
20 70 T1C N0M0 ENEG, PNEG, K40%, C3+ III IDC
C: c-erb; E: estrogen receptor; K: Ki67; NEG: negative; P: progesteron receptor; TNM: tumor, node, metastasis; IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular
Carcinoma; DCIS: In situ Ductal Carcinoma; TIS: In SituTumor.
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Figure 1 RT-PCRs determination of selected genes in BC tissues. Samples from tumor (T) and nontumor (NT) tissues were treated and
analyzed as described in Methods. The PCR products were fractionated by 1.2% agarose gel electrophoresis. (A) Representative RT-PCR
experiments from three independent replicas are shown. (B) Densitometric analyses of PCR gel bands, obtained from patients, represent the
measurements done on three separate experiments. Data were pooled and analyzed to produce an average level of expression. Alternatively,
gene of interest/b-actin or/GADPH ratios (normalized for each experimental time point) have been used for normalization. An arbitrary
densitometric unit bar graph (SD) is shown. The p values (< 0.01) were measured with the Student’s t test.
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by these two Spm analogues are consistent with their
predicted interaction mode observed in the modeled
complexes. In fact, CPENSpm displays a much higher
affinity for mSMO with respect to BENSpm and this is
likely due to the cyclopropyl substituent present in
CPENSpm which can be easily accommodated in the
highly hydrophobic pocket formed by three Tyr residues
with a total contact surface of approx. 73 Å2. This
increase in hydrophobic contact surface area with
respect to BENSpm is expected to improve the binding
affinity of CPENSpm, according to known semiempirical
expression of the relationship between contact surface
and hydrophobic interactions energy [33], as indeed
observed experimentally (Table 3).
Discussion
This is the first investigation demonstrating that SMO
expression in BC tissues is significantly lower than in
nonneoplastic tissues, by RT-PCR and enzyme activity
analyses.
It has been proposed that the H2O2 produced during
the oxidation of PA by SMO may contribute to the level
Figure 2 SMO, APAO, ODC and SSAT activities. Enzyme activities from tumor (T) and nontumor (NT) samples were assayed as described in
Methods section. Results are mean (SD) with n value of 20. The p values (< 0.05) were measured with Wilcoxon matched pairs signed rank test.
Table 2 Enzyme activities in human BC tissues
S N SMO activity (pmolH2O2/
mgprotein/h)
APAO activity (pmolH2O2/mg
protein/h)
ODC activity (pmolCO2/mg
protein/h)
SSAT activity (pmolCO2/mg
protein/h)
T 20 159.1 (024.8) 190.8 (048.9) 244.5 (53.7) 2,150.0 (343.0)
NT 20 653.2 (161.1) 631.4 (164.1 19.0 (05.2) 598.0 (071.8)
S, sample; N, patient number. Samples T (tumor) and samples NT (non tumor) were collected as described and store at -80°C until assayed for SMO, APAO, ODC
and SSAT activity, as described in Methods. Values are mean (SD).
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of apoptosis in BC cell lines [11,15]. Thus, it is tempting
to speculate that the significant decreases in SMO activ-
ity that we observed in BC tissues may contribute to
tumor growth through a decreased rate of endogenous
apoptosis resulting from decreases in the local concentra-
tions of H2O2. SMO dysregulation has also been
observed in prostate cancer, by using image analysis tech-
niques and TMAJ software tools [34], and in ulcerative
colitis, by TaqMan-based real-time PCR [35]. In both
cases the level of SMO expression was observed to be
upregulated. To explain these apparently contradictory
results of SMO expression the process of carcinogenesis
has to be considered. It is well known that a large num-
ber of human cancer types has been directly associated to
chronic inflammation, a temporally limited adaptive
response. During inflammation there is an oxidative
stress and many evidences point out that SMO activity
participates in producing reactive oxygen species (H2O2)
Figure 3 Schematic representation of the putative complexes formed by mSMO with the substrate Spm (A), the inhibitor MDL 72527
(B), and the analogues BENSpm (C) and CPENSpm (D). For details see Methods section.
Figure 4 Chemical structures of SMO substrates and inhibitors.
Chemical structures of Spm, the specific substrate of SMO enzyme,
of MDL 72527 (N1, N4-bis(2,3-butadienyl)-1,4butanediamine), an
inhibitor of SMO, and of Spm-derivative analogues BENSpm (N1,
N11-di(ethyl)norspermine) and CPENSpm (N1-cyclopropyl-methyl-N11-
ethyl-norspermine). Abbreviations used in the figure are defined in
the text.
Table 3 Values of Ki for BENSpm, CPENSpm and
MDL72527 binding to mSMO enzyme
Inhibitor mSMO Ki (M)
a
BENSpm 3.8 × 10-4
CPENSpm 8.5 × 10-5
MDL72527 6.3 × 10-5
The SD is 5%.
Cervelli et al. BMC Cancer 2010, 10:555
http://www.biomedcentral.com/1471-2407/10/555
Page 7 of 10
[6,36,37]. When the inflammation-driven tumour pro-
gressively develops, the H2O2 produced by oxidation of
PA by SMO and APAO may potentially negatively con-
tribute to cell proliferation. In this scenario, we expected
to observe an inversion tendency of SMO and APAO
gene expression, resulting in a lower ROS production
that no longer contrasts the tumour progression.
In line with this hypothesis, we confirm that APAO
enzyme activity was significantly lower in BC tissue [12],
contributing to a reduction of the cellular H2O2 level.
We also confirm the results of previous studies on
SSAT and ODC enzyme activities carried out in human
BC tissues compared with nonmalignant control, indi-
cating a high ODC and SSAT activities in BC samples
[12,38,39]. Manni et al. [38] reported that increased
ODC activity is associated with an increased risk of
both disease recurrence and death, while Deng
et al. [39] showed that the overexpression of ODC in
BC tissues correlates with the TNM grading system.
Wallace et al. [12] reported that the decrease of APAO
activity in BC tissues positively correlated with the
aggressiveness of the tumor, while the increase of SSAT
activity showed a tendency to be indicative of a poor
prognosis. It was proposed that SSAT and APAO inter-
play could produce an efficient system to generate
locally high concentrations of H2O2 that drives cells to
the death signaling pathway, notwithstanding SMO
activity was not considered in this context [12].
In BC cells this normal death-generating pathway is
blocked by the decrease in activity of APAO and, thus,
acetylPA accumulate within the tissue. AcetylPA, unlike
PA, are not significantly toxic to tumor cells and may,
thus, remain within the tumor cells without causing any
negative effects [12]. On the other hand, the increase in
SSAT activity explains the high level of N1, N12-
diacetylspermine (DiAcSpm) in the urine of BC patients,
which proved to be a more sensitive marker than CEA,
CA19-9 and CA15-3 in BC at early stages [40].
Considering this altered PA homeostasis in BC tissue,
a low gene expression of both SMO and APAO is in
line with the tumoral blocked death-generating pathway
and the high proliferating cellular rate. BENSpm and
CPENSpm have been successfully employed as antiproli-
ferate compounds on some human BC cell lines
[11,15,17,18] but in Phases I and II of clinical trials gave
poor positive outcomes [14,18,20-22]. The H2O2 pro-
duced through BENSpm-induced PA catabolism was
found to be derived exclusively from SMO and not
through APAO activity. This data suggested that SMO
activity is the major mediator of the cellular response of
BC cells to BENSpm and that APAO plays little or no
role in this response [11]. It has been shown that the
utilization of CPENSpm has produced overlapping
results with the BENSpm treatments [22]. We modeled
the structure of the complexes formed by the mSMO
enzyme with BENSpm and CPENSpm. This modeling
analysis, a fast and economic way of screening a large
number of potential Spm analogues, has revealed the
structural bases of the higher affinity that CPENSpm
displays for mSMO active site with respect to BENSpm.
The cyclopropyl substituent present in CPENSpm nicely
fits in a hydrophobic pocket present in mSMO active
site. This interaction, estimated to increase CPENSpm
affinity for mSMO, is absent in the modeled BENSpm-
mSMO. To confirm that these molecules impair mSMO
activity, the inhibition of this enzyme activity by
BENSpm and CPENSpm was analyzed. Values of Ki for
mSMO competitive inhibition by these two Spm analo-
gues indicate that they can be considered good in vitro
inhibitors of SMO activity, with CPENSpm being more
reactive than BENSpm. These results are apparently in
contradiction with previous data reported by Wang
et al. [41], indicating that both BENSpm and CPENSpm
molecules are poor inhibitors of the human SMO
enzyme. However, in that work the authors were search-
ing for strong SMO inhibitors and used a very low inhi-
bitor concentration (10 μM) compared to substrate
concentration (250 μM). The high Spm concentration
utilized in Wang’s experiments would explain the poor
inhibition observed [41]. In our experimental conditions
the BENSpm and CPENSpm concentration was in the
range of 10-4 M in the presence of 5-10 × 10-6 M Spm.
BENSpm and CPENSpm show Ki values (3.8 × 10
-4 M
and 8.5 × 10-5 M, respectively) comparable to that of
MDL72527 (6.3 × 10-5 M), which can be considered a
good inhibitor of SMO activity [42]. The finding that
both BENSpm and CPENSpm are inhibitors of the SMO
catalytic activity could explain their SMO induction
effect as a cellular mechanism to overwhelm enzyme
inhibition. This novel finding on the inhibitory proper-
ties of BENSpm and CPENSpm should not be underesti-
mated and could explain the clinical trials failure of
BENSpm. Nevertheless, a key question is to understand
how intracellular SMO and SSAT up-regulations are
exerted by BENSpm and CPENSpm treatment. One
hypothesis is that these analogues compete with natural
PA for uptake when using the PA transporter to gain
entry into the cell [5].
Conclusions
Data in this article highlight the clinical importance of
SMO expression in breast tumors. SMO enzyme is an
important PA catabolic component that could play a
crucial role in BC disease and still remains a promising
therapeutic target for cancer and hyperproliferation.
This is the first study demonstrating that SMO activity
in BC tissues is significantly lower than in controls. Low
SMO activity may contribute to tumor growth through
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a decrease of the local H2O2 concentration. Up-
regulation of SMO activity can lead to an increase of
apoptosis rate. Spm analogues able to induce SMO
activity can be utilized in anticancer therapy. Two Spm
analogues, BENSpm and CPENSpm, capable of produ-
cing cytotoxicity on some human BC cell lines by SMO
induction, have been in silico analyzed and then in vitro
tested. Both analogues resulted to be inhibitors of SMO
activity. Their inhibition properties could explain their
failure in clinical trials. The in silico Spm analogues
screening together with the availability of the recombi-
nant SMO enzyme could be relevant to in vitro test
analogues able to up-regulate SMO, before their utiliza-
tion in clinical trials. Hopefully, new selected Spm ana-
logues could be utilized as antineoplastic drugs with
novel action mechanisms.
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